Approval · Notice of Compliance 3315 · 1997
ALPHAGAN: Notice of Compliance 3315
Issued November 24, 1997
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 3315
- Date
- November 24, 1997
- Company
- Allergan IncMarkham, Ontario, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- New Drug Submission (NDS)
- Submission class
- New Active Substance (NAS)
- Therapeutic class
- Elevated intraocular pressure therapy (relatively selective alpha 2-adrenoreceptor agonist)
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| ALPHAGAN | 02236876 | Marketed |
| ALPHAGAN | 02236877 | — |
Medicinal ingredients
- BRIMONIDINE TARTRATE 0.2 PER
- BRIMONIDINE TARTRATE 0.5 PER